Drug Profile


Alternative Names: AZD 6474; Caprelsa; SAR 390530; Zactima; ZD 6474; Zictifa

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; Fox Chase Cancer Center; Hoosier Cancer Research Network; Sanofi; University of Oxford
  • Class Antineoplastics; Bromobenzenes; Fluorobenzenes; Piperidines; Quinazolines; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists; Proto oncogene protein c ret inhibitors; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Thyroid cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Thyroid cancer
  • Phase II Malignant melanoma; Small cell lung cancer
  • No development reported Brain metastases; Gastrointestinal cancer
  • Discontinued Biliary cancer; Breast cancer; Colorectal cancer; Head and neck cancer; Hepatocellular carcinoma; Malignant pleural effusion; Mesothelioma; Non-small cell lung cancer; Ovarian cancer; Prostate cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Gastrointestinal-cancer(Combination therapy, Late-stage disease) in USA (PO, Tablet)
  • 01 Aug 2017 AstraZeneca completes a phase I trial in Gastrointestinal cancer (Late-stage disease, Combination therapy) in USA (PO)
  • 27 Jul 2017 AstraZeneca completes the phase III VERIFY trial for Thyroid cancer (Late-stage disease) in USA, Brazil, China, Japan, Russia, Denmark, France, Italy, Poland, Spain, Czechia and Sweden (PO) (NCT01876784)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top